Ambys Medicines
Holger Willenbring, M.D, Ph.D. is a Professor of Surgery and associate director of the Liver Center at the University of California, San Francisco Medical Center. Holger is a member of the Eli and Edyth Broad Center of Regeneration Medicine and Stem Cell Research, and his research focus is on liver regeneration and liver cell transplantation, mechanisms of hepatocarcinogenesis, and approaches to the treatment and reversal of liver fibrosis.
Holger received his medical education from Medical University Lübeck, Germany, Harvard Medical School, and the University of Münster, Germany, where he also completed his residency in pediatrics. He completed his postdoctoral work at Oregon Health & Science University in Portland, Oregon, in the Department of Molecular and Medical Genetics.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.